About Transcell Biosciences
Transcell Biosciences is a Healthcare company based in Hyderabad (India) founded in 2009. Stem cell banking and biobanking services are provided by Transcell Biosciences. It operates on a Managed Services and HealthTech model. Transcell Biosciences has raised $2.24 million across 6 funding rounds from investors including Lemon Tree Hotels, Quantiphi and Primarc. Transcell Biosciences was last valued at $11.59 million in July 2024. Transcell Biosciences offers products and services including ScellCare, PREGEN, HSCT, BARTI, and TRUCB. Its focus areas include Biotechnology and Stem Cell Technology. Its legal entity is Transcell Biolife.
Company details
Stem cell banking and transformative medicinal applications are facilitated by Transcell Biosciences. Based in India, the company focuses on biobanking functions for personalized healthcare solutions. Services include cord blood storage, predictive advisory, stem cell transplantation, regenerative implants, plasma fractionation, population omics, and drug discovery. The healthcare sector is primarily served, with an emphasis on patient-centric and data-driven approaches. Innovative solutions are developed to address over 80 diseases through stem cell technology.
- Annual Revenue$55.72 K (USD)-37as on Mar 31, 2023
- Net Profit-$86.22 K (USD)-18as on Mar 31, 2023
- EBITDA$3.44 K (USD)-88as on Mar 31, 2023
- Total Equity Funding$2.24M (USD)
in 6 rounds
- Latest Funding Round$38.63K (USD), Seed
May 2026
- InvestorsLemon Tree Hotels
& 72 more
Associated legal entities of Transcell Biosciences
Transcell Biosciences is associated with 3 registered companies on The Company Check. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Transcell Biosciences Private Limited CIN U24290TG2022PTC162503 | Active | 11 May 2022 | Hyderabad, Telangana | ₹5.6 Cr | 2 | View details | |
| Transcell Biolife Private Limited CIN U74999TG2017PTC118697 | Amalgamated | 03 Aug 2017 | Hyderabad, Telangana | ₹2.9 Cr | 2 | View details | |
| Tran-Scell Biologics Private Limited CIN U85100TG2009PTC066172 | Active | 07 Dec 2009 | Hyderabad, Telangana | ₹1.4 Cr | 18 | 4 | View details |
Products & Services of Transcell Biosciences
Transcell Biosciences offers a comprehensive portfolio of products and services, including ScellCare, PREGEN, HSCT, BARTI, and TRUCB.
Cord blood units are collected and stored compliantly.
Predictive and advisory services are provided with registration.
Damaged bone marrow is replaced for treatment.
Natural healing is promoted with tooth implants.
Plasma yields are enhanced for industrial applications.
Transformative medicinal applications are optimized through data.
Innovative drug solutions are developed for health.
Funding Insights of Transcell Biosciences
Transcell Biosciences has successfully raised a total of $2.24M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $38.63 thousand completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.24M
- Total Rounds 6
- Last Round Seed — $38,631
- First Round $139,471
(Nov 2015)
- Investors Count 73
All 6 funding rounds of Transcell Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $38,631 | Seed | – | – | – |
| Jul 2024 | $1.39M | Series A | $11.59M | Quantiphi | |
| Dec 2022 | Seed | – | Indian Angel Network | ||
| Apr 2017 | $301,905 | Seed | $1.99M | – | |
| Feb 2016 | $377,075 | Seed | $••••• | Vikas Kuthiala, Vivek Chanana | |
| Nov 2015 | $139,471 | Seed | $••••• | – |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2024 | $11.59M | •••••••• |
| Apr 2017 | $1.99M | •••••••• |
| Feb 2016 | $••••• | •••••••• |
Full valuation and stage history of Transcell Biosciences
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $11.59M (Jul 2024). 73 investors in total: 17 institutional and 56 angel.
Investors in Transcell Biosciences
Transcell Biosciences has secured backing from 73 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Lemon Tree Hotels, Quantiphi and Primarc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Angel investor network investing in early-stage startups | iangroup.vc | Delhi, India | ||
Venture capital firm focused on seed-stage investments | parekhmarketing.tcc.mode | Mumbai, India | ||
Private investment arm of Kris Gopalakrishnan Family Office. | 2014 | pratithi.com | Bengaluru, India | |
Technology company focused on building bonds through software. | 2012 | graycellventures.com | Chandigarh, India | |
Venture capital investments are focused on healthcare and diverse sectors. | spankmanagement.tcc.mode | Delhi, India | ||
Provider of AI and machine learning services | 2013 | quantiphi.com | Marlborough, United States | |
Early stage investments are made in innovative Indian startups. | 2006 | indianangelnetwork.com | New Delhi, India | |
Real estate investments are managed for risk-adjusted returns by Pragnya. | pragnyafunds.com | Port Louis, Mauritius | ||
Offers fundraising services for progressive organizations and candidates through donor campaigns. | 1988 | telefund.com | Chicago, United States | |
Creates and manages commercial office parks for IT and other sectors in Hyderabad. | 1982 | garcorp.in | Hyderabad, India |
Investor details for Transcell Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Transcell Biosciences
The boards of the 3 registered companies of Transcell Biosciences currently have 5 directors; the longest-serving is Subhadra Dravida, appointed in 2009. 17 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Subhadra Dravida DIN 02680118 | Managing Director | 07 Dec 2009 | 16 yrs 10 mo | Tran-Scell Biologics Private Limited, Transcell Biosciences Private Limited, Transcell Biolife Private Limited |
| Vinayender Tulla DIN 01041344 | Director | 05 Oct 2015 | 11 yrs | Tran-Scell Biologics Private Limited |
| Uday Chatterjee DIN 00492413 | Director | 11 May 2020 | 6 yrs 5 mo | Tran-Scell Biologics Private Limited, Transcell Biosciences Private Limited |
| Gorthi Leelakrishna DIN 09479117 | Director | 25 Jan 2022 | 4 yrs 9 mo | Transcell Biolife Private Limited |
| Asif Wahidul Hasan DIN 06612304 | Director | 25 Jul 2024 | 2 yrs 3 mo | Tran-Scell Biologics Private Limited |
Financials of Transcell Biosciences
Figures of Tran-Scell Biologics Private Limited, the primary company behind Transcell Biosciences, for FY 2025. Revenue was ₹1.44 Cr (+1134% year on year). Net loss was -₹1.61 Cr (-112% margin). EBITDA was -₹89.4 Lakh (-62% margin). Revenue has grown at a compounded annual rate of +27% over three years and -6% over five years.
- ₹1.44 CrRevenue · FY 2025 · +1134% YoY
- -₹1.61 CrNet loss · -112% margin
- -₹89.4 LakhEBITDA · -62% margin
- ₹3.14 CrPaid-up capital
- 18Employees (provident fund records)
- +27%Revenue CAGR, 3 years
- -6%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Tran-Scell Biologics Private Limited are on its company page.
Detailed financial statements for Transcell Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Transcell Biosciences
4 dated milestones of Transcell Biosciences across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Transcell Biosciences is founded.
- Funding First funding round of $139K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Seed, of $39K.
Web traffic of Transcell Biosciences
The website of Transcell Biosciences (transcell.in) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Transcell Biosciences
Complete news archive for Transcell Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transcell Biosciences
Transcell Biosciences was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Transcell Biosciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Transcell Biosciences is a funded company, having raised a total of $2.24M across 6 funding rounds to date. The company's 1st funding round was a Seed of $139.47K, raised on Nov 2015.
Annual revenue of Transcell Biosciences is $55.72K as on Mar 31, 2023.
Stem cell banking and transformative medicinal applications are facilitated by Transcell Biosciences. Based in India, the company focuses on biobanking functions for personalized healthcare solutions. Services include cord blood storage, predictive advisory, stem cell transplantation, regenerative implants, plasma fractionation, population omics, and drug discovery. The healthcare sector is primarily served, with an emphasis on patient-centric and data-driven approaches. Innovative solutions are developed to address over 80 diseases through stem cell technology.
Transcell Biosciences offers ScellCare, PREGEN, HSCT, BARTI, and 3 more products and services.
Transcell Biosciences has 73 investors. Key investors include Lemon Tree Hotels, Quantiphi, Primarc, Pidilite, and ADVIK Hi-Tech.
The valuation of Transcell Biosciences is $11.59M as of Jul 2024.
Transcell Biosciences is associated with 3 legal entities: Tran-Scell Biologics Private Limited, Transcell Biosciences Private Limited, Transcell Biolife Private Limited.
The legal entities of Transcell Biosciences currently have 5 directors, including Uday Chatterjee, Vinayender Tulla, Subhadra Dravida and others.